MAPEC and Hygia trials (Hermida 2010-2020): bedtime antihypertensive dosing reduced cardiovascular events vs morning; data later contested by methodological critique.
MAPEC and Hygia trials (Hermida 2010-2020): bedtime antihypertensive dosing reduced cardiovascular events vs morning; data later contested by methodological critique.